Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen- activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate

Journal of Vascular Surgery

Volumn 31, Issue 6, 2000, Pages 1214-1228

  Kibbe, Melina R ^a,c   Li, Jianrong ^a   Nie, Suhua ^a   Watkins, Simon C ^a   Lizonova, Alena ^b   Kovesdi, Imre ^b   Simmons, Richard L ^a   Billiar, Timothy R ^a   Tzeng, Edith ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b GENVEC INC   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PROTEIN P53; VIRUS VECTOR;

ANIMAL CELL; ARTERY INJURY; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; GENE TRANSFER; HEMOSTASIS; LEUKOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0033916814     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2000.105006     Document Type: Article

References (61)

1. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997;40:141-58.
2. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993;193:291-6.
3. Davies MG, Kim JH, Dalen H, Makhoul RG, Svendsen E, Hagen PO. Reduction of experimental vein graft intimal hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine. Surgery 1994;116:557-68.
4. Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res 1995;30:87-96.
5. Lee JS, Adrie C, Jacob HJ, Roberts JDJ, Zapol WM, Bloch KD. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 1996;78:337-42.
6. von der Leyen, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-41.
7. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, et al. Efficient inhibition of intimai hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998;187:295-306.
8. Shears LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi, I et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997;100:2035-42.
9. Janssens S, Flaherty D, Nong Z, Varenne O, Van Pelt N, Haustermans, C et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998;97:1274-81.
10. Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98:919-26.
11. Kibbe M, Billiar T, Tzeng E. Nitric oxide synthase gene transfer to the vessel wall [in process citation]. Curr Opin Nephrol Hypertens 1999;8:75-81.
12. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-6.
13. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A 1993;90:3491-5.
14. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997;95:1269-77.
15. Tzeng E, Yoneyama T, Hatakeyama K, Shears LL, Billiar TR, Vascular inducible nitric oxide synthase gene therapy: requirement for guanosine triphosphate cyclohydrolase I. Surgery 1996;120:315-21.
16. Tzeng E, Billiar TR, Robbins PD, Loftus M, Stuehr DJ. Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A 1995;92:11771-5.
17. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A 1993;90:522-6.
18. Kim YM, de Vera ME, Watkins SC, Billiar TR. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factoralpha-induced apoptosis by inducing heat shock protein 70 expression. J Biol Chem 1997;272:1402-11.
19. Tzeng E, Shears LL, Robbins PD, Pitt BR, Geller DA, Watkins SC, et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med 1996;2:211-25.
20. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG. L-No-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37: 3886-8.
21. Cornwell TL, Soff GA, Traynor AE, Lincoln TM. Regulation of the expression of cyclic GMP-dependent protein kinase by cell density in vascular smooth muscle cells. J Vasc Res 1994;31:330-7.
22. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol 1997;272(4 Pt 2):H1810-8.
23. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 1997;272:10050-7.
24. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54:1169-74.
25. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 1997;3:441-51.
26. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
27. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-7.
28. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Nad Acad Sci U S A 1996;93:2442-7.
29. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997;11:443-8.
30. Mii S, Khalil RA, Morgan KG, Ware JA, Kent KC. Mitogenactivated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 1996;270(1 Pt 2):H142-50.
31. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-35.
32. Janssens S, Flaherty D, Nong Z, Varenne O, Van Pelt N, Haustermans C, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998;97:1274-81.
33. Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998; 98:919-26.
34. Chen L, Daum G, Forough R, Clowes M, Walter U, Clowes AW. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res 1998;82:862-70.
35. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987;84:9265-9.
36. Murad F, Rapoport RM, Fiscus R. Role of cyclic-GMP in relaxations of vascular smooth muscle. J Cardiovasc Pharmacol 1985;(7 Suppl 3):S111-8.
37. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
38. Kariya K, Kawahara Y, Araki S, Fukuzaki H, Takai Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1989;80:143-7.
39. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990;189:347-53.
40. Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 1990;171:474-9.
41. Heller R, Polack T, Grabner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 1999;144:49-57.
42. Sandirasegarane L, Diamond J. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation [in process citation]. J Mol Cell Cardiol 1999;31:799-808.
43. Summers BA, Overholt JL, Prabhakar NR. Nitric oxide inhibits L-type Ca2+ current in glomus cells of the rabbit carotid body via a cGMP-independent mechanism. J Neurophysiol 1999;81:1449-57.
44. Tsikas D, Ikic M, Tewes KS, Raida M, Frolich JC. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP- independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets. FEBS Lett 1999; 442:162-6.
45. Phung YT, Bekker JM, Hallmark OG, Black SM. Both neuronal NO synthase and nitric oxide are required for PC12 cell differentiation: a cGMP independent pathway. Brain Res Mol Brain Res 1999;64:165-78.
46. Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollman MJ, Gibbons GH, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 1999;99:1236-41.
47. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72.
48. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases. Cell 1993;75:805-16.
49. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
50. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimai cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A 1996;93:7905-910.
51. Ho YS, Wang YJ, Lin JK. Induction of p53 and p21/WAF1/CIPl expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog 1996;16:20-31.
52. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 1994;11:59-64.
53. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994;9:3389-96.
54. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 1996;271:18961-5.
55. Qiu X, Forman HJ, Schonthal AH, Cadenas E. Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. J Biol Chem 1996;271:31915-21.
56. Lander HM, Jacovina AT, Davis RJ, Tauras JM. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 1996;271:19705-9.
57. Callsen D, Pfeilschifter J, Brune B. Rapid and delayed p42/p44 mitogen-activated protein kinase activation by nitric oxide: the role of cyclic GMP and tyrosine phosphatase inhibition. J Immunol 1998;161:4852-8.
58. Kanterewicz BI, Knapp LT, Klann E. Stimulation of p42 and p44 mitogen-activated protein kinases by reactive oxygen species and nitric oxide in hippocampus. J Neurochem 1998;70:1009-16.
59. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinasel/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-6.
60. Lander HM, Ogiste JS, Pearce SF, Levi R, Novogrodsky A. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J Biol Chem 1995;270:7017-20.
61. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998;394:295-9.